Rasburicase bulk supplier for pharma manufacturers

Rasburicase 1.5 mg/1.5 mL (1.5 mg vial) Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1.5 mg/1.5 mL (1.5 mg vial)

Reference Brands: Elitek® (US & EU)

Rasburicase is used to treat tumor lysis syndrome (TLS) in cancer patients, especially those with leukemia and lymphoma. Available as 1.5 mg vials under the brand Elitek® in the US and EU, it helps reduce elevated uric acid levels. Ideal for oncology B2B pharma distributors.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Rasburicase? List it or send an offer →

Product Description: Rasburicase is an enzyme therapy used for the prevention and treatment of tumor lysis syndrome (TLS) in patients with hematologic malignancies, such as leukemia and lymphoma. It is a recombinant urate oxidase that helps lower elevated uric acid levels, which can occur after chemotherapy. Available under the brand Elitek®, Rasburicase is marketed in 1.5 mg vials for injection in the US and EU. Manufactured under GMP-compliant standards, it is a vital product for oncology B2B pharma distributors and is supplied for use in hospitals and treatment centers globally.

Rasburicase — third party manufacturing & bulk supply

Rasburicase 1.5 mg/1.5 mL (1.5 mg vial) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Rasburicase is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Rasburicase listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Rasburicase →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Rasburicase is listed as Injection in 1.5 mg/1.5 mL (1.5 mg vial). Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Rasburicase is referenced against Elitek® (US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.